Biohaven Ltd BHVN

NYS: BHVN | ISIN: VGG111961055   14/11/2024
48,66 USD (-0,77%)
(-0,77%)   14/11/2024

8 augustus 2024 · Biohaven Reports Second Quarter 2024 Financial Results and Recent Business Developments · Persbericht

29 mei 2024 · Biohaven Showcases Broad Innovative Portfolio and Pipeline Updates Across Multiple Therapeutic Areas including Immunology, Neuroscience, Metabolic Disorders and Oncology at Annual Investor R&D Day · Persbericht

29 mei 2024 · Biohaven Doses First Patient with its Novel Trop-2 Directed Antibody Drug Conjugate (ADC) BHV-1510 in Advanced or Metastatic Epithelial Tumors · Persbericht

9 mei 2024 · Biohaven Reports First Quarter 2024 Financial Results and Recent Business Developments · Persbericht

22 april 2024 · Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares · Persbericht

18 april 2024 · Biohaven Announces Pricing of $230 Million Public Offering of Common Shares · Persbericht

17 april 2024 · Biohaven Announces Proposed Public Offering of Common Shares · Persbericht

13 april 2024 · Biohaven Showcases Innovative Neuroscience Portfolio with 20 Presentations at the 2024 American Academy of Neurology (AAN) Annual Meeting and Provides Other Business Updates · Persbericht

29 februari 2024 · Biohaven Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Developments · Persbericht

8 januari 2024 · Biohaven Highlights Progress Across Innovative Portfolio and Outlines 2024 Anticipated Milestones at the 42nd Annual J.P. Morgan Healthcare Conference; Established Extensive Portfolio Across 20 Therapeutic Indications in Neuroscience, Immunology and Oncology · Persbericht

2 januari 2024 · Biohaven to Present at the 42nd Annual J.P. Morgan Healthcare Conference · Persbericht

1 december 2023 · Biohaven Presents Expanded EEG and Safety Data for BHV-7000 at the American Epilepsy Society Annual Meeting · Persbericht

16 oktober 2023 · Biohaven Presents Preclinical Data Demonstrating Taldefgrobep alfa Reduces Fat and Improves Lean Mass at The Obesity Society's Annual Meeting, ObesityWeek® · Persbericht

5 oktober 2023 · Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares · Persbericht

3 oktober 2023 · Biohaven Announces Pricing of $225 Million Public Offering of Common Shares · Persbericht

2 oktober 2023 · Biohaven Announces Proposed Public Offering Of Common Shares · Persbericht

14 september 2023 · Biohaven Completes Enrollment in Pivotal Phase 3 Study of Taldefgrobep Alfa in Spinal Muscular Atrophy · Persbericht

5 september 2023 · Biohaven Announces Positive Data from its Exploratory Electroencephalogram (EEG) Biomarker Study of BHV-7000, Completion of Once-Daily Formulation Development, and Plan to Initiate Phase 3 Pivotal Studies · Persbericht

31 juli 2023 · Biohaven's Taldefgrobep Alfa Receives EU Orphan Drug Designation for Spinal Muscular Atrophy · Persbericht

31 juli 2023 · Biohaven Reports Second Quarter 2023 Financial Results and Recent Business Developments · Persbericht

Mijn selecties